Addition of MgSO4 or Dexamethasone to Bupivacaine on the Prolongation of Ultrasound-guided Quadratus Lumboram Block

Ain Shams University

Status: Completed

Conditions: Post Operative Pain

Treatments: Drug: Bupivacaine- Magnesium; Drug: Bupivacaine saline; Drug: Bupivacaine dexamethasone

Study type: Interventional

Funder types: Other

Identifiers

NCT05397236

FMASU MS 256/2021

Details and patient eligibility

About

The goal of postoperative pain management is the provision of comfort, early mobilization and improved respiratory function without causing inadequate sedation and respiratory compromise, which can be achieved through using regional anethesia.

This study aimed to assess the analgesic effect of adding dexamethasone or magnesium sulphate with bupivacaine in ultrasound-guided QLB to prolong its duration in patients undergoing open abdominal surgeries in the early postoperative period regarding pain relief After approval of the ethical committees in Ain Shams University Hospitals, patients undergoing open abdominal surgeries were included in the study, and were divided into three groups (n=22; each); group M, D and group C. In Group A, patients (n=22) received 20 ml bupivacaine 0.25% plus 5 ml of 10% MgSO. In group B, patients (n=22) received 20 ml bupivacaine 0.25% plus 8 mg dexamethasone (2 ml) plus 3 ml 0.9% NaCl. In group C (control), patients (n=22) received 20 ml bupivacaine plus 5 ml 0.9% NaCl.

Enrollment: 66 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Society of Anesthesiologists (ASA) physical status I or II
• aged 18 to 65 years
• body weight ≥ 60 kg and ≤ 90 kg
• scheduled for open abdominal surgeries

Exclusion criteria

• Patients' refusal to participate in the study
• history of allergy to the medications used in the study
• hepatic disease
• renal disease
• known neurologic disorders
• psychiatric disorder
• chronic treatment with calcium channel blockers
• hyper-magnesemia
• coagulopathy
• anatomical abnormalities
• hemodynamic instability
• local infection
• suspected intra- abdominal sepsis

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

66 participants in 3 patient groups

Bupivacaine Magnesium sulphate group

Active Comparator group

Description:

Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.

Treatment:

Drug: Bupivacaine- Magnesium

Bupivacaine Dexamethasone group

Active Comparator group

Description:

Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.

Treatment:

Drug: Bupivacaine dexamethasone

bupivacaine saline group

Active Comparator group

Description:

Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.

Treatment:

Drug: Bupivacaine saline